VERAXA Biotech Demonstrates Dose-Dependent Breast Cancer Cell Kill with BiTAC-ADC
VRXA•VERAXA Biotech reported new in vitro proof-of-concept data for its BiTAC-ADC platform, demonstrating dose-dependent destruction of breast cancer cell spheroids while sparing healthy cells. The company will showcase its BiTAC-ADC and BiTAC-TCE platforms for strategic collaboration at BIO International Convention 2026 in San Diego.
1. In Vitro Proof-of-Concept Data
VERAXA Biotech announced that its BiTAC-ADC platform achieved selective, dose-dependent destruction of three-dimensional breast cancer cell spheroids in vitro, while healthy cells remained unaffected. These results validate the platform’s mechanism to activate cytotoxic payloads only in targeted tumor environments.
2. Pipeline Diversification and Collaboration Plans
The company’s oncology pipeline includes antibody-drug conjugates, T-cell engagers and other antibody-based modalities, all leveraging its proprietary BiTAC approach. VERAXA will present both BiTAC-ADC and BiTAC-TCE platforms at BIO International Convention 2026 to engage potential pharmaceutical and biotechnology collaborators.
3. NASDAQ Listing and Corporate Progress
Following its business combination with Voyager Acquisition Corp, VERAXA began trading on the NASDAQ Capital Market under the ticker VRXA. The public listing enhances liquidity and visibility as the company advances its next-generation cancer therapy programs.
